We are proud of the progress we made in 2020 towards building an antibiotic portfolio and achieving our 5 BY 25 goal: to deliver five new treatments to tackle drug-resistant infections that pose the greatest threat to health by 2025.
a landmark observational study on neonatal sepsis and finalised a clinical study report on the pharmacokinetic clinical trial assessing the safety and dosing of fosfomycin in newborns.
one potential antibiotic combination of fosfomycin-amikacin to treat neonatal sepsis.
first agreement of GARDP’s Serious Bacterial Infections programme and started the first project to bring a new drug to market.
patient enrolment in the US and activated a new site in The Netherlands, as part of our phase 3 trial of a new treatment for gonorrhoea.
17 REVIVE webinars and launched a new online Antimicrobial Encyclopaedia.
over 24,000 compounds from five different partners. Daiichi Sankyo joined the GARDP-led Antimicrobial Resistance Screening Consortium alongside Eisai and Takeda.
The 2020 Activity Report shows GARDP’s progress and promise in the fight against the most serious drug-resistant infections. It also demonstrates why more partnerships and investment are critical to address the growing threat of antibiotic resistance and achieve the Sustainable Development Goals.Download full report